Indegene Limited will engage with investors and analysts during the Investec Healthcare Roadtrip scheduled for June 3, 2026, in New Jersey, United States of America. This meeting provides stakeholders an opportunity to discuss the company's performance and outlook based on publicly available information.

The event is an in-person group meeting, allowing for direct interaction between company officials and investors. The disclosure regarding this meeting was filed with a delay, attributed to the short notice with which the schedule was confirmed.

The company has acknowledged the delay in submitting the intimation under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Indegene stated that it will endeavor to ensure timely intimation of future meetings in compliance with regulatory requirements.

The information regarding the meeting has been made available on the official website of Indegene Limited .

Indegene Limited submitted a revised investor presentation to BSE Limited and the National Stock Exchange of India Limited regarding its analyst meet held from May 27 to May 29, 2026. The filing, made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, corrected a duplicate page in the earlier submission while confirming no material change in disclosed information. Signed by Company Secretary and Compliance Officer Srishti Ramesh Kaushik, the presentation outlines the company's positioning as a strategic operating partner for life sciences, built for the AI Decade.

FY26 Financial Performance at a Glance

Indegene reported strong financial metrics for FY26, underpinned by sustained client deepening and revenue expansion. The company highlighted a zero-debt balance sheet and Net Revenue Retention (NRR) above 100% every year as key indicators of client stickiness and business quality.

Client Growth: Expanding Breadth and Depth

The presentation detailed significant expansion in active client relationships and revenue concentration among high-value accounts between FY21 and FY26. Indegene serves as a key partner to 20 of the Top 20 and 80 of the Top 100 global life sciences companies.

Client Tiering and Mid-Term Growth Roadmap

Indegene presented a structured client migration framework across four tiers, with a stated long-term vision of building a multi-billion enterprise through a large deal engine. As of FY26, the company had 91 active clients, with the top 10 holding 51% of revenue.

The company identified high-potential accounts with $150–200M potential as priority targets, and cited a $2B+ vision supported by a high-talent team focused on consulting-led selling.

Market Opportunity and AI-Driven Structural Tailwinds

The presentation outlined the global pharma industry's trajectory from $1.4Tn to $2Tn+ by 2030, with a sector CAGR consistently above GDP at 5%–7%, annual R&D and commercial spend globally exceeding $500B, and an average drug lifecycle of 12–15 years. Outsourced life sciences operations spend was cited as growing from $54B to approximately $100B between 2024 and 2030.

Indegene highlighted five structural reasons it views GenAI as a tailwind rather than a headwind:

• Revenue Partner, not Cost Partner: Embedded in revenue-generating commercial and medical workflows, with spend growing alongside client revenue.
• Different Buyer Group: Decisions made by Commercial, Medical Affairs, and Regulatory leaders, accessing growth-oriented budget pools.
• Domain-led, Judgment-intensive: Therapeutic, regulatory, and MLR expertise built over 27 years, with AI augmenting rather than replacing domain judgment.
• Outcome-aligned Commercial Model: Volume-linked and outcome-based contracts where efficiency gains accrue to margin.
• Disruptor, not the Disrupted: Unlocking budget from agencies and CROs, with early-stage TAM penetration providing multi-year runway.

Pharma Services TAM and Centralization Dynamics

The presentation provided a function-by-function view of total addressable market, outsourcing penetration, and centralization trends through 2030.

The Medical Affairs, Regulatory, and PV market was cited at approximately $30B, growing at 10–12%. The Sales and Marketing agency wallet was described as approximately $50B across five buckets—Creative & Brand ($18B), MedEd & Med Comms ($10B), HCP Digital & Omnichannel ($8B), DTC & Patient Media ($9B), and Analytics & Insights (~$5B)—with Indegene positioning itself to capture consolidating spend across all segments.

FY27 Outlook and Strategic Priorities

Entering FY27, the company noted that its pipeline is 17% higher than at the same point the prior year, with balanced strength across Top-20 and Outside-Top-20 client cohorts. Key strategic priorities highlighted include:

• Traction in new solutions including Tectonic and Medical Writing
• M&A-driven capability expansion through acquisitions of Cult, Trilogy, Biopharm, Warn, and Cake Communications, adding local credibility and enabling expansion from regional to global engagements
• Continued AI platform investment to deepen domain-anchored, outcome-priced service delivery

The presentation concluded by referencing Indegene's current scale of approximately $400M, with a stated near-term target of $500M+, framing its 27-year operating history as the foundation for capturing the AI-era life sciences services opportunity.